Close
Smartlab Europe
Inizio Ignite

Aptar Pharma names Jean-Marc Pardonge as prescription division new president

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.
- Advertisement -

Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company’s prescription division.

The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices.

In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted to R&D vice president in 2003.

In January 2010, Pardonge served as global market development president for Aptar Pharma’s prescription division, where he managed and coordinated worldwide activities which included scientific and regulatory affairs, business development, communication, engineering, innovation, marketing, projects and R&D.

The market for prescription division will be leveraged with Pardonge’s knowledge in both the pharmaceutical market and the division’s customers, claims the company.

 

Latest stories

Related stories

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.

Drug Device Combination Products Driving Delivery Precision

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »